Progyny (NASDAQ: PGNY), a fertility benefits management company, saw its shares fall 6% on Friday after the company reported second-quarter results showing a 5% increase in sales (or 11% excluding the loss of a major client last year) and a 15% increase in adjusted earnings per share, both exceeding Wall Street expectations. However, management's guidance for third-quarter sales growth of only 7% to 11%, along with an anticipated slight sequential decline in earnings, triggered a negative market reaction.